0001104659-22-045308.txt : 20220413 0001104659-22-045308.hdr.sgml : 20220413 20220413091531 ACCESSION NUMBER: 0001104659-22-045308 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220408 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20220413 DATE AS OF CHANGE: 20220413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 22823812 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm2212581d1_8k.htm FORM 8-K
0001551152 false 0001551152 2022-04-08 2022-04-08 0001551152 us-gaap:CommonStockMember exch:XNYS 2022-04-08 2022-04-08 0001551152 exch:XCHI us-gaap:CommonStockMember 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes1.500Percentdue2023Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2022-04-08 2022-04-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 8, 2022

 

ABBVIE INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35565   32-0375147
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

 

 

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code:        (847) 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange
Chicago Stock Exchange
1.500% Senior Notes due 2023   ABBV23B   New York Stock Exchange
1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange
1.250% Senior Notes due 2024   ABBV24B   New York Stock Exchange
0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange
2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange
2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange
2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange
1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02               Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On April 8, 2022, Michael E Severino informed AbbVie that he will be departing as AbbVie’s Vice Chairman and President, effective May 31, 2022. He will be joining a bioplatform innovation company as CEO-Partner and as CEO of one of its companies.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABBVIE INC.
     
Date:  April 13, 2022 By: /s/ Timothy J. Richmond
    Timothy J. Richmond
    Executive Vice President, Chief Human Resources Officer

 

 

 

EX-101.SCH 2 abbv-20220408.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 abbv-20220408_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 abbv-20220408_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] NEW YORK STOCK EXCHANGE, INC. [Member] CHICAGO STOCK EXCHANGE, INC [Member] Senior Notes 1.500 Percent due 2023 [Member] Senior Notes 1.375 Percent due 2024 [Member] Senior Notes 1.250 Percent due 2024 [Member] Senior Notes 0.750 Percent due 2027 [Member] Senior Notes 2.125 Percent due 2028 [Member] Senior Notes 2.625 Percent due 2028 [Member] Senior Notes 2.125 Percent due 2029 [Member] Senior Notes 1.250 Percent due 2031 [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Senior Notes 0.500 Percent due 2021 Senior Notes 1.500 Percent due 2023 Senior Notes 1.375 Percent due 2024 Senior Notes 1.250 Percent due 2024 Senior Notes 0.750 Percent due 2027 Senior Notes 2.125 Percent due 2028 Senior Notes 2.625 Percent due 2028 Senior Notes 2.125 Percent due 2029 Senior Notes 1.250 Percent due 2031 EX-101.PRE 5 abbv-20220408_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Apr. 08, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 08, 2022
Entity File Number 001-35565
Entity Registrant Name ABBVIE INC.
Entity Central Index Key 0001551152
Entity Tax Identification Number 32-0375147
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1 North Waukegan Road
Entity Address, City or Town North Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 847
Local Phone Number 932-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name NYSE
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]  
Document Information [Line Items]  
Security Exchange Name CHX
Senior Notes 1.500 Percent due 2023 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.500% Senior Notes due 2023
Trading Symbol ABBV23B
Security Exchange Name NYSE
Senior Notes 1.375 Percent due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.375% Senior Notes due 2024
Trading Symbol ABBV24
Security Exchange Name NYSE
Senior Notes 1.250 Percent due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2024
Trading Symbol ABBV24B
Security Exchange Name NYSE
Senior Notes 0.750 Percent due 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 0.750% Senior Notes due 2027
Trading Symbol ABBV27
Security Exchange Name NYSE
Senior Notes 2.125 Percent due 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2028
Trading Symbol ABBV28
Security Exchange Name NYSE
Senior Notes 2.625 Percent due 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 2.625% Senior Notes due 2028
Trading Symbol ABBV28B
Security Exchange Name NYSE
Senior Notes 2.125 Percent due 2029 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2029
Trading Symbol ABBV29
Security Exchange Name NYSE
Senior Notes 1.250 Percent due 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2031
Trading Symbol ABBV31
Security Exchange Name NYSE
XML 7 tm2212581d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001551152 2022-04-08 2022-04-08 0001551152 us-gaap:CommonStockMember exch:XNYS 2022-04-08 2022-04-08 0001551152 us-gaap:CommonStockMember exch:XCHI 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes1.500Percentdue2023Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2022-04-08 2022-04-08 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2022-04-08 2022-04-08 iso4217:USD shares iso4217:USD shares 0001551152 false 8-K 2022-04-08 ABBVIE INC. DE 001-35565 32-0375147 1 North Waukegan Road North Chicago IL 60064-6400 847 932-7900 false false false false Common Stock, $0.01 Par Value ABBV NYSE CHX 1.500% Senior Notes due 2023 ABBV23B NYSE 1.375% Senior Notes due 2024 ABBV24 NYSE 1.250% Senior Notes due 2024 ABBV24B NYSE 0.750% Senior Notes due 2027 ABBV27 NYSE 2.125% Senior Notes due 2028 ABBV28 NYSE 2.625% Senior Notes due 2028 ABBV28B NYSE 2.125% Senior Notes due 2029 ABBV29 NYSE 1.250% Senior Notes due 2031 ABBV31 NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .Y)C50'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #N28U4[JIL[^\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NDD9AZCK96BG(2$Q"<0M2KPMHDFCQ*C=VY.6K1."!^ 8^\_G MSY(;':3N(S['/F DB^EN=)U/4HGWI]&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #N28U49"-H#X$& #B* & 'AL+W=O./G9"3!>/WQ912@1ZR-"].:U,A9F\;C2*: MTHP4=3:CN?QFS'A&A-SEDT8QXY3$NE&6-K#CA(V,)'GM[$1_-N1G)VPNTB2G M0XZ*>981_GA.4[8XK;FUIP^ND\E4J \:9R#;G<:ZQ5XB2C>9&P M''$Z/JUUW+?G85LUT$=\3NBBV-A&ZE+N&+M7._WXM.8H1S2ED5 21/[[2;LT M3962]/%C)5I;GU,UW-Q^4G^O+UY>S!TI:)>EMTDLIJ>U5@W%=$SFJ;AFBPNZ MNJ! Z44L+?1?M%@=Z]10-"\$RU:-I8,LR9?_R<.J$!L-O&T-\*H!UKZ7)](N MWQ%!SDXX6R"NCI9J:D-?JFXMS26YZI61X/+;1+839UWVD_*3AI!2ZH-&M&IV MOFR&MS3KS'@=.:TCA!V,?VW>D [6-O#:!M9ZWA:]=RR:R[X6J)\ODZ9Z[-M' M>13J"YH5WX%S>.MS>/H'B,9H-*ZP$HZ"JVCW]Z\L60A7%L+0<%> M+A+QB-XG*46#>797GD]8PW'<8R\(P@#PTUS[:>[BYYI.DD)P(FLV(%EIH6"= MSOGYYWX/]0?=.N"JM7;5VL555_8A)ZD<-S%]0)?TL,SQK6W M(S02,ON(<=1E-I &XE5>[@R6 M=-& <3%%MV1^3R,Q)!9@VX7[V6VJ_9D*6_8(B\U"LLM;7:G,C<3!ADT MW'=ALV?\(63.S@0OC_+FU(2N$',W_)+/M"8050[D< M\X]#WW$@@V::<&&ZZ\[LR/7>=C^P0 L>MV92<&&B?V21+,QPRG)H5K"(M"5, MFFVX-&9:<&&>W_)$")K+PF39/%]AKBAU!0O9YG37S DNC/(12Y,H$4D^09]D MQGE"TE(_L(K5CYD,7)C=0TZ/(UD>*@?9$O_P7HV9]A, Q@& M]0MG_:*82V"=IH!>1OE$]><'J:"XR+(9R4MG>8N@U=K&6ATF MM J\G-!'@D7WZ-LGJ@;C=_0O&O1NT=>KZTLTNKGJ7J+>E^Y%9_"A=Z27/.L# M(0L&Z=@[V/T"-G3&,$MO$B'7H&R,7/SGW5]H1*.Y'//EQ8>5-DMVA'YWZHZ+ MAH2CSR2=@YUB0(UASMYP$JN@_1E.03 MNG6];!$:?!U!RREL2(UAP&X+;/>BW^U\N"K+ZTYQ-5S&KCSY/L5YMD0ULO/%R2#4$]F*#[)!E6TL4K3[(/636L M]>#5ZPY)A@5TDD$OALA>542V"%F"[!LD^WLA&0O7&L_^ M U!+ P04 " #N28U4GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67= MA['-HN6/O.-%Q[I#)6 M,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-? MRA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@# ME_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\ M;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/! MI!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V, MD_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]? M\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD M\%G'!QR>(W?#$T%^@2O M&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R M^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%N MV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@/ M/GL?)=-[*CG_5U/\!%!+ P04 " #N28U4EXJ[', 3 @ "P %]R M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_: MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$ MVV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( .Y)C52JQ"(6,P$ "(" M / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V- MB??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C! MVWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$ M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R#/; M@L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V M&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N M\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG M5LJ]AU>RY1AQ_)[E#U!+ P04 " #N28U4)!Z;HJT #X 0 &@ 'AL M+U]R96QS+W=O[IFBG#S^0W1UW6E\./VR./ / M,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G M>1,)KM\,<'AT_@%02P,$% @ [DF-5&60>9(9 0 SP, !, M !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 ! M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G M8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9# ML9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/ MN]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DW MY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " #N M28U4!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P M+GAM;%!+ 0(4 Q0 ( .Y)C53NJFSO[P "L" 1 " M :\ !D;V-0&UL4$L! M A0#% @ [DF-5&0C: ^!!@ XB@ !@ ("!#@@ 'AL M+W=OH3 !X;"]?7!E&UL4$L%!@ ) D /@( !D6 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 11 22 1 false 11 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbvie.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2212581d1_8k.htm abbv-20220408.xsd abbv-20220408_def.xml abbv-20220408_lab.xml abbv-20220408_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2212581d1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 11, "dts": { "definitionLink": { "local": [ "abbv-20220408_def.xml" ] }, "inline": { "local": [ "tm2212581d1_8k.htm" ] }, "labelLink": { "local": [ "abbv-20220408_lab.xml" ] }, "presentationLink": { "local": [ "abbv-20220408_pre.xml" ] }, "schema": { "local": [ "abbv-20220408.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd" ] } }, "elementCount": 76, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 8, "memberStandard": 3, "nsprefix": "abbv", "nsuri": "http://abbvie.com/20220408", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2212581d1_8k.htm", "contextRef": "From2022-04-08to2022-04-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://abbvie.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2212581d1_8k.htm", "contextRef": "From2022-04-08to2022-04-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 11, "tag": { "abbv_SeniorNotes0.750Percentdue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.750 Percent due 2027", "label": "Senior Notes 0.750 Percent due 2027 [Member]" } } }, "localname": "SeniorNotes0.750Percentdue2027Member", "nsuri": "http://abbvie.com/20220408", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_SeniorNotes1.250Percentdue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.250 Percent due 2024", "label": "Senior Notes 1.250 Percent due 2024 [Member]" } } }, "localname": "SeniorNotes1.250Percentdue2024Member", "nsuri": "http://abbvie.com/20220408", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_SeniorNotes1.250Percentdue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.250 Percent due 2031", "label": "Senior Notes 1.250 Percent due 2031 [Member]" } } }, "localname": "SeniorNotes1.250Percentdue2031Member", "nsuri": "http://abbvie.com/20220408", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_SeniorNotes1.375Percentdue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.375 Percent due 2024", "label": "Senior Notes 1.375 Percent due 2024 [Member]" } } }, "localname": "SeniorNotes1.375Percentdue2024Member", "nsuri": "http://abbvie.com/20220408", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_SeniorNotes1.500Percentdue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.500 Percent due 2023", "label": "Senior Notes 1.500 Percent due 2023 [Member]" } } }, "localname": "SeniorNotes1.500Percentdue2023Member", "nsuri": "http://abbvie.com/20220408", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_SeniorNotes2.125Percentdue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.125 Percent due 2028", "label": "Senior Notes 2.125 Percent due 2028 [Member]" } } }, "localname": "SeniorNotes2.125Percentdue2028Member", "nsuri": "http://abbvie.com/20220408", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_SeniorNotes2.125Percentdue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.125 Percent due 2029", "label": "Senior Notes 2.125 Percent due 2029 [Member]" } } }, "localname": "SeniorNotes2.125Percentdue2029Member", "nsuri": "http://abbvie.com/20220408", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "abbv_SeniorNotes2.625Percentdue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.625 Percent due 2028", "label": "Senior Notes 2.625 Percent due 2028 [Member]" } } }, "localname": "SeniorNotes2.625Percentdue2028Member", "nsuri": "http://abbvie.com/20220408", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2021", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2021", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://abbvie.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-045308-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-045308-xbrl.zip M4$L#!!0 ( .Y)C52D,X37*P0 *\5 1 86)B=BTR,#(R,#0P."YX M7*#[>I'$Z)$(23GK6;[C68BPD$>437K6AY'] M9G35[UOH]:O??D7P=7^W;71#21QUT#4/[3X;\Y?H+4Y(!]T21@167+Q$'W&< MZA%^0V,BT!5/9C%1!":RE3JHY?B-$-GV'KH?"8NX^'#?+W6G2LUDQW7G\[G# M^".><_$@G9 G^PF.%%:I+-6\A9=_^]&'5(8E^05^TYI?+.[IYPEAE^D -[^$ MG_"GP5UP%_WSY?X%_OMAH9(_YD'P<,Z>AO'X@="?T/(/2 AJ1#9PD MH3/ACRY, +[A?SLKH*FT)QC/2O@8R\#(YA,&;GN^W?0+BA1J&PZ#NZ&V>IH1 MN9.03>V@14ILT-9V$J9=/:V9GF8V2B8.@L>2I#N4Z/S6R(9WYEW"*8U)0IBZ MX2*Y)F."7KDZ2CN Q>0]!(]V 0[E+64^Y5QS*BH5HU+.RIM8 1:,2D3%EU"R5GST? MV?JDI=H4- VEZVZ"5R122:([]LJT9X)(X)G8!S"0$W-(!2G$<9C&AW&6H>RD MY /%'BUWK3A?]V2,S+GLZ!_?LR35E='*QZ:"C'N6WDB[^#E?P9H#.5% M'3- MN30[O[D;^<*%!!;AELI6W0 1/B-"44CLE>*0A4Z5IK];60;I=:2%W!]A.<;! MH9:!0N*?Z'6@]7^H2R;)*J7HF.TX*@"R"*>'K%[B3>N@=2L?8OLE0\'*$D&_S;XC M*7<_[8X-Y)F4S-]SYKVD;XJO(\(H%V^Y(M)W6I[WCH@0 %%*0*,Y)$F@GU?3>7&-1*HQ+>$]F_>)! MVXEX@BGK*Y)H).Q*"N)4I1I]*W@*+_%,C@)D;YO-B]9:Z&'-#\%U!+ P04 " #N M28U4PGA=U0@* 0?0 %0 &%B8G8M,C R,C T,#A?9&5F+GAM;-6=6U?C MMA;'W\]:_0YI^IP[# ,=3A>3@9ZL,D )G;;G)4NQE40+1>+(,B3?OI(O(7:T M%8=#E-$\,"'>V_KO_9-ULVP^_;*8T]HS%A'A[+S>:;;K-U7S'# DDN?JY]0S36W_ K0K&H]?G\B6*)U8&TX+/:<;/3#6J-1H7S?L,L MY.*/^\'JO#,IGZ*S5NOEY:7)^#-ZX>(Q:@9\7NV$0XED'*W.UEZTLW^I^R=* MV..9_C%&$:ZI?+'H;!&1\[HN-ROVI=?D8MKJMMN=UE]?KX?!#,]1@S"=MP#7 MJUM]."Z*;&<>DUT M1,ZB)))K'B"9U)"MBFJ@A?ZMD9LU]%>-3K?1ZS0745C/.27)%ISB>SRIZ?\5 MZ%6I:#Q^)EB3;>E#K3Y7-5?I3)QF D_.Z]I$G;O;;1^U/^HS_U0PDLLG58,C MHBM@O=8JE(I$D!=L,EXO!8@Q3[4.[C@I?*9.(8)XC!LAF6.F*WN]EA6T'MGJ M+(3)EC)M938MXPGVKWM56"/DY>U*R^)HSH9NY:_5K0C1=2]3HXS)7K M$U9KE221VC3K43JUANY^8J5$JH^I928BET%Y4"B;ZK:7B\VD17FT$0Z:4_[< M"C%1F>MV_G>D/S;2CVGJ,!GEY>JN3\Q1%B<>2#R/\I-3-,8T*7*D7.P>+4>Z M+YG*X?*:1%*-2:('-'ZM0$6Y1L.RRE?(%R+7F]60BI=A6BW/ LZDJA:7%.L4 MJ:J-I_I#+FTB^+QB(K.D<7L@ZZE5>NHU+D(LU)"M_2J)\@B'YW4I8D/DN_.9 MH&B"DG>6N[9[[T8MB0X"USLT.#Z?A3&6-GVP&QK MWRJN(U/5^2ZROU,$X(6Q3QJ]D^."H*/J- #7T9$W-&P10#2.]DFC>]Q^*PW M=73L#0U;!!"-X_W1:#=/2H).JM( 74 43C9)\T/KR=!N Z^N@-#5L$$(V/+J^-T[=?&YGKZ-0;&K8((!JG M#GOQ7N?-O7CNJD;KGN#8$@*\]O4N"REO68>\7 0SQ*886-3:6$ JVG^O*UI; M9(.K)PXI9(+ 11(=0LG&\7)5M21R4.Y^UZCVE>;O<@WJ_T/A8.$IIX%5P=FB MD_J4T$A8Z-]&?]W\/30@T,?T(>?+2'"=Y09E8./]KJV&/8']_PR@!*I#(].5 M=?@$YLK ]L!AYY??P7I09[7?+-06H\X!,KKC3;9-O5">'3:[%TI1J%5=430U MY[E@XD.B#8+!)N$ F?Z"HT"0)[DV:@(2OF;I5=XW='\'P[@\EGL\53VS2()9 MW2FR-S!&%Q^ 5 @ '&RX)W/!6(SH/7[B8@N0=4N?.&SJ!E?OW:?_]Q@)B05= M5B%0,O8)@E$ZN&Y_@ &/0&H.HJ.I J)L[1,)LW9PT=X]BN$,4ZKWCB-6Z:K8 MM/<)!Z0>7+<_+)#+9SW24)U9=28K%U^QE ( U_#=D[G#@O!0#2Y$!28E8Y]H M&*6#J_>'XG#)PJH4,E/_&!2$P^OU[A%7>"S)%8#DFPO?$IV_H#P:PT"+0:B"(A.2/F*]'0;@X@\3:P @&H?3Z%3F@ 5SS MT-IE6!W]P50A#!"6P[EV*O8B# 6.HNP_'5S'ALA@[@\84#QX8\_ESB% 8G<5)QQM5KH[4TCL.!=U@ M_IU/SS-U=SR2B/Z7/&T;\9KLO6-A4 \2<3A;SZJ(7L^!MJ@53'S(NT$PF&J' M4W+=45T(C.#JOF[A1:(W]()Y=CB_ON;Z-M6,,^NZ=]G*AWR;-8,Y=SE-UJ^P MBL F9'78ARR7Q$+I?=]'-.SI_5,0J43I-V;$+%O6 NYN&DU]2+M%.(C X51W MR"D)B'[,YZL:W J"J#G_FW8^)!]2#6;>X:SV3F!=*;":220["?6[\L3M9 *U M[+"]#R2VJ0>).)S>EC0.HBC&8ET@%B !DYG.H.<1"K%G79Z8X?]%LB M@=:J9.4# [-F,.<.I[8?XXN;+T:0EU4=Z.*9DB^,E.BX-/)$#Y$!33J_;V!25]R&XMHBOUP8S#:.H# M"(MP$('+1YWCD$@;'=> !=?=7?IW^VQD3![^ /$IA_DXOQF\8!)+% @R3/^@B3*1-NXF#W\X6+3 M#W)QOL$[N8K[JJ^;
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end